Back
Sarepta Therapeutics, Inc. (SRPT)
BiotechnologySRPT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$18.93
+4.38%Weekly undervalued picks (like SRPT)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-7.13
ROE
4.9%
Gross margin
21.6%
Debt/Equity
0.70x
Revenue growth
-1.9%
Sarepta Therapeutics, Inc. — company intelligence
Earnings surprises
Q2 2026$-0.05 vs $0.26 est-119.0%
Q1 2026$2.88 vs $1.01 est+184.7%
Q4 2025$-3.93 vs $-1.26 est-213.0%
Q3 2025$-0.01 vs $-0.83 est+98.8%
Analyst consensus · 33 analysts
14 Buy13 Hold6 Sell
Updated Aug 11, 2026
Insider activity · 90 days
10 buys0 sellsnet +3,115,446 shares
SEVERINO MICHAELBuy 2,224,342 · Jul 28, 2026
SEVERINO MICHAELBuy 756,104 · Jul 28, 2026
Boor Kathryn JeanBuy 16,875 · Jun 4, 2026
Recent SEC filings
8-K — Material event reportAug 5, 2026
10-Q — Quarterly reportAug 5, 2026
4 — Insider transaction reportJul 29, 2026
Latest news
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated — Yahoo · 2w ago
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... — Yahoo · 2w ago
Sarepta Therapeutics Q2 Earnings Call Highlights — Yahoo · 2w ago
Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook — ChartMill · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like SRPT)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.